Grozeo Strengthens Industry Partnerships at Spring Fair 2025
BIRMINGHAM, United Kingdom, March 04, 2025 (GLOBE NEWSWIRE) -- Grozeo, a retail technology company focused on simplifying e-commerce, participated in Spring Fair 2025, the UK's largest wholesale trade event held at NEC Birmingham. With over 38,000 visitors and 1,400 suppliers in attendance, the event provided a platform for industry leaders to discuss key retail trends, supply chain challenges, and the increasing role of digital transformation.
As retailers seek more efficient ways to manage supply chains and adapt to digitalisation, innovative solutions have become essential. Grozeo's presence at the event reinforced its commitment to supporting businesses through technology-driven retail solutions and fostering strong supplier-retailer relationships.
Facilitating Retailer-Supplier Collaboration
Industry discussions at Spring Fair 2025 highlighted the importance of streamlining procurement and fostering efficient supplier-retailer interactions. Businesses increasingly seek solutions that simplify sourcing, improve supply chain efficiency, and enhance operational effectiveness.
According to Elvijs Plugis, Chief Revenue Officer at Grozeo, retailers require practical tools to connect with suppliers and optimise processes. 'Retailers need seamless solutions to manage supplier relationships and enhance efficiency,' Plugis said. 'Spring Fair 2025 provided an excellent opportunity to engage with industry leaders and explore ways technology can support retail growth.'
Expanding Global Supply Networks
Grozeo also engaged with international suppliers, particularly those from China, to explore new sourcing opportunities for UK retailers. Strengthening these relationships aims to provide businesses with access to a broader selection of high-quality products and improve competitiveness in an evolving retail market.
David Ko, International Sourcing Manager at Grozeo, emphasised the importance of global supply networks. 'Retailers benefit from access to diverse suppliers, enabling them to offer a broader range of products,' Ko said. 'Discussions at Spring Fair reinforced the role of international partnerships in improving supply chain accessibility for UK businesses.'
The Role of Technology in Retail Growth
Discussions at the event also underscored the increasing adoption of AI-driven analytics and automated procurement tools. Retailers are leveraging technology to optimise inventory management, refine pricing strategies, and gain real-time insights into consumer trends.
Maria Mesablishvili, Digital Marketing Manager at Grozeo, noted the growing role of digital tools in modern retail. 'Retailers are adopting data-driven strategies to stay competitive,' Mesablishvili said. 'Spring Fair 2025 highlighted how businesses are prioritising technology to improve decision-making and operational efficiency.'
Spring Fair 2025 served as a valuable forum for retailers, suppliers, and industry professionals to exchange ideas and establish new business relationships. As the retail landscape continues to evolve, Grozeo remains focused on delivering solutions that support business growth and operational agility.
William Tulloch, Head of Partnerships at Grozeo, highlighted the importance of continued collaboration. 'Spring Fair provided key insights into the future of retail,' Tulloch said. 'Grozeo looks forward to further engaging with industry stakeholders to drive innovation and efficiency.'
About Grozeo
Grozeo is a retail technology platform that enables retailers to establish online stores in just two minutes, with no coding or technical expertise required. The platform simplifies e-commerce by allowing retailers to add products seamlessly from a digital product gallery and collaborate with manufacturers, wholesalers, and peer retailers. Grozeo is dedicated to making online retail more accessible, efficient, and scalable for businesses of all sizes.
For more information about Grozeo, visit www.grozeo.com.
Media Contact:Name: Elvijs PlugisDesignation: CROMobile number: +44 7549945392Email: info@grozeo.co.ukWebsite: https://www.grozeo.com/
Disclaimer: This content is provided by the Grozeo. The statements, views, and opinions expressed in this column are solely those of the content provider. The information shared in this press release is not a solicitation for investment, nor is it intended as investment, financial, or trading advice. It is strongly recommended that you conduct thorough research and consult with a professional financial advisor before making any investment or trading decisions. Please conduct your own research and invest at your own risk.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/414d2604-b30a-4685-b18e-65c0c7810119Sign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
New Toll Brothers Stonegate Court Model Home Opens in Gilbert, Arizona
Exclusive community offers single-family homes with private amenities in sought-after Gilbert GILBERT, Ariz., June 16, 2025 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation's leading builder of luxury homes, announced the grand opening of its model home at Stonegate Court, an exclusive new gated community featuring just 22 expansive single-story homes on 15,000+ square foot home sites in Gilbert, Arizona. The stunning Markham model home showcases beautiful farmhouse architecture with fresh modern organic interior design and an incredible resort-style backyard. The Toll Brothers model home grand opening event at Stonegate Court will be held on Saturday, June 21 from 11 a.m. to 4 p.m. at 4229 S. Quinn Ave. in Gilbert. 'The newly opened Markham model home exemplifies the exceptional luxury designs that Toll Brothers offers at Stonegate Court, providing home shoppers with a first-hand look at the sophisticated features and finishes that define Toll Brothers homes,' said Bob Flaherty, Group President of Toll Brothers in tucked between a handful of well-established neighborhoods, Stonegate Court's enclave-like setting offers homebuyers an ideal blend of sophisticated living and modern convenience. The community features three, single-level floor plans ranging from 3,466 to 4,126+ square-feet with 3 to 6 bedrooms, 3.5 to 5.5 baths, and 3- to 4-car garages, with a wide array of personalization options including private multi-generational living suites, expansive multi-slide doors, courtyards, wine rooms, exterior fireplaces, and more. Homes are priced starting at $1.38 million. The intimate setting of the community provides a serene escape for residents, while being ideally located within the desirable Higley Unified School District and near major commuter routes and premier shopping, dining, and outdoor recreation. Toll Brothers customers will experience one-stop shopping at the Toll Brothers Design Studio. The state-of-the-art Design Studio allows customers to choose from a wide array of selections to personalize their dream home with the assistance of Toll Brothers professional Design Consultants. For more information on Stonegate Court or other Toll Brothers communities in Arizona, call (844) 836-5263 or visit Toll Brothers Toll Brothers, Inc., a Fortune 500 Company, is the nation's leading builder of luxury homes. The Company was founded 58 years ago in 1967 and became a public company in 1986. Its common stock is listed on the New York Stock Exchange under the symbol 'TOL.' The Company serves first-time, move-up, empty-nester, active-adult, and second-home buyers, as well as urban and suburban renters. Toll Brothers builds in over 60 markets in 24 states: Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Indiana, Maryland, Massachusetts, Michigan, Nevada, New Jersey, New York, North Carolina, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Virginia, and Washington, as well as in the District of Columbia. The Company operates its own architectural, engineering, mortgage, title, land development, smart home technology, and landscape subsidiaries. The Company also develops master-planned and golf course communities as well as operates its own lumber distribution, house component assembly, and manufacturing operations. Toll Brothers has been one of Fortune magazine's World's Most Admired Companies™ for 10+ years in a row, and in 2024 the Company's Chairman and CEO Douglas C. Yearley, Jr. was named one of 25 Top CEOs by Barron's magazine. Toll Brothers has also been named Builder of the Year by Builder magazine and is the first two-time recipient of Builder of the Year from Professional Builder magazine. For more information visit From Fortune, ©2025 Fortune Media IP Limited. All rights reserved. Used under license. Contact: Andrea Meck | Toll Brothers, Senior Director, Public Relations & Social Media | 215-938-8169 | ameck@ Photos accompanying this announcement are available at: Sent by Toll Brothers via Regional Globe Newswire (TOLL-REG)Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 minutes ago
- Yahoo
Opportunities in the Central Nervous System (CNS) Therapeutics Market: Revenues Forecast to Reach US$156.5 Billion by 2030
Growth is driven by the increasing prevalence of neurological disorders like Alzheimer's, Parkinson's, and schizophrenia, fueled by aging populations and heightened mental health awareness. North America leads the market, with significant growth anticipated in Asia-Pacific due to rising mental health consciousness and improved healthcare access. Central Nervous System Therapeutics Market Dublin, June 16, 2025 (GLOBE NEWSWIRE) -- The "Central Nervous System Therapeutics - Global Strategic Business Report" has been added to global market for Central Nervous System Therapeutics was valued at US$107 Billion in 2024 and is projected to reach US$156.5 Billion by 2030, growing at a CAGR of 6.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Central Nervous System Therapeutics market. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as AbbVie Inc., Allergan plc, Anavex Life Sciences Corp., AstraZeneca plc, and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. The global CNS therapeutics market is growing due to increasing disease burden, heightened awareness of mental and neurological health, and the rapid advancement of therapeutic science. Unmet needs across multiple CNS indications, combined with demographic pressures and healthcare digitization, are generating sustained demand for both novel and reformulated therapies. Public and private sector investments in neuroscience research, along with regulatory support for orphan drug development and accelerated pathways, are further incentivizing companies are expanding pipelines through acquisitions, collaborations, and AI-enabled drug discovery platforms focused on CNS targets. At the same time, patient advocacy, digital care models, and personalized treatment paradigms are shifting the industry toward more holistic, outcomes-driven approaches. As complexity in CNS care deepens and precision treatment becomes more attainable, a defining question shapes the market's future: Can CNS therapeutics continue to evolve through biomarker-guided innovation, cross-disciplinary care models, and scalable delivery platforms while addressing the dual challenge of clinical uncertainty and global accessibility?Key Insights: Market Growth: Understand the significant growth trajectory of the Analgesics segment, which is expected to reach US$46.6 Billion by 2030 with a CAGR of a 8.6%. The Anti-Cholinergic Agents segment is also set to grow at 4.6% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $29.2 Billion in 2024, and China, forecasted to grow at an impressive 10.6% CAGR to reach $32.9 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Key Questions Answered: How is the Global Central Nervous System Therapeutics Market expected to evolve by 2030? What are the main drivers and restraints affecting the market? Which market segments will grow the most over the forecast period? How will market shares for different regions and segments change by 2030? Who are the leading players in the market, and what are their prospects? Some of the 44 companies featured in this Central Nervous System Therapeutics market report include: AbbVie Inc. Allergan plc Anavex Life Sciences Corp. AstraZeneca plc Biogen Inc. Bristol Myers Squibb Cipla Limited Dr. Reddy's Laboratories Ltd. Eli Lilly and Company GlaxoSmithKline plc H. Lundbeck A/S Johnson & Johnson Lupin Limited Merck & Co., Inc. Novartis AG Otsuka Pharmaceutical Co., Ltd. Pfizer Inc. Roche Holding AG Takeda Pharmaceutical Company Ltd. Teva Pharmaceutical Industries Ltd. This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include: Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs. Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes historical analysis since 2015. Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends. Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape. Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players. Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities. Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage. Key Attributes Report Attribute Details No. of Pages 395 Forecast Period 2024-2030 Estimated Market Value (USD) in 2024 $107 Billion Forecasted Market Value (USD) by 2030 $156.5 Billion Compound Annual Growth Rate 6.5% Regions Covered Global MARKET OVERVIEW Influencer Market Insights World Market Trajectories Central Nervous System Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E) MARKET TRENDS & DRIVERS Rising Prevalence of Alzheimers, Parkinsons, and Epilepsy Fuels Demand for CNS Drug Innovation Biologics, Gene Therapies, and Small Molecules Converge in Development Pipelines for CNS Disorders Cross-BBB Delivery Technologies and Neurotargeted Carriers Address Long-Standing Bioavailability Barriers Psychiatric Disorders Like Depression and Bipolar Drive Growth in Multimodal CNS Treatment Strategies Digital Therapeutics and CNS Drug Monitoring Tools Expand Clinical Management Capabilities Patient-Centered Outcome Measures Gain Priority in CNS Trial Designs and Payer Decisions High Unmet Need in Rare Neurological Conditions Spurs Orphan Drug Development Activity Aging Demographics and Lifestyle Shifts Expand CNS Therapeutic Demand Across Regions For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Central Nervous System Therapeutics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Hamilton Spectator
19 minutes ago
- Hamilton Spectator
LambdaTest Launches Accessibility MCP Server to Enhance Web Accessibility Testing
San Francisco, CA, June 16, 2025 (GLOBE NEWSWIRE) — LambdaTest , a unified agentic AI and cloud engineering platform, has unveiled its Accessibility MCP Server , a powerful new solution designed to streamline accessibility testing for modern web applications. This server empowers developers to identify, understand, and resolve accessibility issues in both publicly hosted websites and front-end React applications still in development. By leveraging the Model Context Protocol (MCP), the server simplifies the integration of AI assistance, enabling efficient interaction with accessibility tools. Users receive detailed, actionable insights that not only highlight accessibility barriers but also guide teams through effective remediation. The Accessibility MCP Server currently offers three core tools: an Accessibility Report that instantly generates a comprehensive accessibility report for public URLs, A local build app tool allowing developers to build and serve their local React app to identify accessibility issues during development and Analyze App that helps in local app tests analysis, which are already running in LambdaTest via LambdaTest tunnel for accessibility failures. LambdaTest's Accessibility MCP Server generates comprehensive reports that can be shared across teams, supporting collaborative issue resolution. Developers using AI assistants such as Cline can connect to the server with minimal setup. Once connected, Cline can automatically analyze websites or local apps, deliver accessibility reports, and even suggest or implement fixes directly within the codebase. For local development, developers can serve their application through a LambdaTest Tunnel and instruct Cline to analyze the app. The tool identifies accessibility violations, provides automated suggestions for remediation, and delivers a detailed report. This workflow enables developers to address compliance directly within their development environment. 'At LambdaTest, our mission is to empower developers with tools that make building inclusive digital experiences both simple and scalable,' said Jay Singh, Co-Founder and Head of Product at LambdaTest. 'The Accessibility MCP Server is a major step forward in that vision—bridging the gap between accessibility compliance and everyday development workflows through the power of AI and seamless automation.' To learn more about Accessibility MCP Server, please visit About LambdaTest LambdaTest is an AI-native, omnichannel software quality platform that empowers businesses to accelerate time to market through intelligent, cloud-based test authoring, orchestration, and execution. With over 15,000 customers and 2.3 million+ users across 130+ countries, LambdaTest is the trusted choice for modern software testing. For more information, please visit
